Vectura in partnership with UCB are working on developing a new asthma drug
The 2 pharmaceutical companies have joined forces to develop a new asthma drug. This would include a large antibody molecule delivered as a dry powder.
The drug has successfully passed phase I – checking its safety and tolerability in healthy patients.
The chief executive of Vectura has expressed his contentment with the results and collaboration and emphasised the importance of starting preparations for phase II of the study.
For more details please click HERE.